ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

A number of other analysts have also issued reports on ANIP. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Barclays assumed coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price objective for the company. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Finally, Guggenheim upped their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Trading Down 2.8%

ANIP opened at $70.49 on Friday. ANI Pharmaceuticals has a 52 week low of $56.71 and a 52 week high of $99.50. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. The business has a fifty day simple moving average of $79.12 and a 200-day simple moving average of $85.35. The firm has a market cap of $1.58 billion, a P/E ratio of 20.98 and a beta of 0.52.

Insider Activity at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,312 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $75.50, for a total transaction of $552,056.00. Following the completion of the transaction, the chief financial officer directly owned 185,543 shares of the company’s stock, valued at approximately $14,008,496.50. The trade was a 3.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Thomas Andrew Rowland sold 4,772 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the sale, the senior vice president owned 38,730 shares in the company, valued at $2,901,264.30. The trade was a 10.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 29,482 shares of company stock worth $2,248,424 over the last quarter. 11.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership acquired a new position in ANI Pharmaceuticals during the 3rd quarter worth approximately $32,992,000. Balyasny Asset Management L.P. raised its holdings in shares of ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after purchasing an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at $21,454,000. Rubric Capital Management LP lifted its position in shares of ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after purchasing an additional 200,998 shares during the last quarter. Finally, UBS Group AG lifted its position in shares of ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Zacks/analyst bullishness — A Zacks piece highlights ANIP among four biotech names to watch for upside in 2026, citing new drug approvals and pipeline progress. Another Zacks story notes the consensus of Wall Street analysts implies roughly a 44.8% upside in ANIP, which could support buying interest if fundamentals continue to improve. 4 Biotech Stocks to Watch for Potential Upside in 2026 Analysts See a 44.84% Upside in ANI (ANIP)
• Neutral Sentiment: Analyst/market coverage piece — Yahoo published a “sizing up” note after a recent share-price pullback that reviews valuation and technicals; such coverage can attract traders looking to buy a dip but doesn’t itself guarantee direction. Sizing Up ANI Pharmaceuticals After Recent Share Price Pullback
• Neutral Sentiment: Short interest data appears non‑informative — a March note shows effectively zero reported short interest (and a 0.0 days-to-cover), suggesting short activity is not currently driving the move. This item is ambiguous given the odd/empty figures provided.
• Negative Sentiment: Insider selling — Several insiders disclosed open-market sales this week: VP Meredith Cook sold 500 shares (avg ~$72.62; SEC filing), insider Christopher Mutz sold 3,162 shares (avg ~$71.64; SEC filing), and SVP Thomas Rowland sold 4,772 shares (avg ~$74.91; SEC filing). Combined, these disclosures show executives trimming positions and likely contributed to downward pressure on the stock today. Meredith Cook Form 4 Christopher Mutz Form 4 Thomas Rowland Form 4

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.